Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies

The Key Acne Companies in the market include - BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others.
DelveInsight's "Acne Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Acne, historical and forecasted epidemiology as well as the Acne market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Acne market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acne Market Forecast [https://www.delveinsight.com/sample-request/acne-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Acne Market Report:

*
The Acne market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In March 2025, Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and fibrotic disorders, announced that its Investigational New Drug (IND) application for TVB-3567 has been cleared. TVB-3567, a potent and selective fatty acid synthase (FASN) inhibitor, is set to enter clinical development for acne treatment. The U.S. Food and Drug Administration's Division of Dermatology and Dentistry has approved the IND, enabling the company to launch a first-in-human Phase 1 clinical trial in 2025.

*
In December 2024, Dermata Therapeutics, Inc. (NASDAQ: DRMA, DRMAW), a late-stage biotechnology company specializing in medical and aesthetic skin conditions, has announced the successful completion of patient enrollment in its pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) study for DMT310. This once-weekly topical treatment is being developed for moderate-to-severe acne. STAR-1 is the first of two Phase 3 trials, and if results are positive, they will support Dermata's submission of a New Drug Application (NDA) for DMT310.

*
Key Acne Companies: BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others

*
Key Acne Therapies: BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF Registered , Imsidolimab, RA-18C3, FMX101, IDP-126, and others

*
The Acne epidemiology based on gender analyzed that females are predominantly affected compared to males

*
The Acne market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acne pipeline products will significantly revolutionize the Acne market dynamics.

Acne Overview

Acne is a common skin condition that occurs when hair follicles become clogged with oil (sebum), dead skin cells, and bacteria. It typically appears as pimples, blackheads, whiteheads, nodules, or cysts, mainly on the face, chest, back, and shoulders.

Acne is often linked to hormonal changes, genetics, stress, diet, and certain medications. While it is most common during adolescence, it can also affect adults. Treatment options include topical creams, oral medications, lifestyle changes, and professional procedures like laser therapy or chemical peels.

Get a Free sample for the Acne Market Report:

https://www.delveinsight.com/report-store/acne-market [https://www.delveinsight.com/report-store/acne-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Acne Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acne Epidemiology Segmentation:

The Acne market report proffers epidemiological analysis for the study period 2024-2034 in the 7MM segmented into:

*
Total Prevalence of Acne

*
Prevalent Cases of Acne by severity

*
Gender-specific Prevalence of Acne

*
Diagnosed Cases of Episodic and Chronic Acne

Download the report to understand which factors are driving Acne epidemiology trends @ Acne Epidemiology Forecast [https://www.delveinsight.com/sample-request/acne-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Acne Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acne market or expected to get launched during the study period. The analysis covers Acne market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acne Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acne Therapies and Key Companies

*
BPX-01: BioPharmX

*
IDP-120: Bausch Health Americas, Inc.

*
GT20029: Kintor Pharma

*
KX-826: KintorPharma

*
S6G5T-3: Sol-Gel Technologies, Ltd.

*
ASC40: Ascletis Pharma

*
GK530G: Galderma R&D

*
Dapsone: Torrent Pharma

*
DMT310: Dermata Therapeutics

*
CD5789 (trifarotene): Galderma R&D

*
Afamelanotide: Clinuvel Pharma

*
NVN1000: Novan, Inc.

*
Hydrogen Peroxide: Dermata Therapeutics

*
Trifarotene Cream: Galderma R&D

*
S6G5T-3: Accelovance

*
GDC 268 Lotion: Balmoral Medical

*
Isotretinoin: Vyne Therapeutics Inc.

*
gevokizumab: XOMA (US) LLC

*
BLI1100: Braintree Laboratories

*
AKLIEF Registered : Teva Pharma

*
Imsidolimab: AnaptysBio, Inc.

*
RA-18C3: Janssen Research

*
FMX101: Cutia Therapeutics

*
IDP-126: Bausch Health

Discover more about therapies set to grab major Acne market share @ Acne Treatment Market [https://www.delveinsight.com/sample-request/acne-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Acne Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Acne Companies: BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others

*
Key Acne Therapies: BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF Registered , Imsidolimab, RA-18C3, FMX101, IDP-126, and others

*
Acne Therapeutic Assessment: Acne current marketed and Acne emerging therapies

*
Acne Market Dynamics: Acne market drivers and Acne market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Acne Unmet Needs, KOL's views, Analyst's views, Acne Market Access and Reimbursement

To know more about Acne companies working in the treatment market, visit @ Acne Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/acne-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Acne Market Report Introduction

2. Executive Summary for Acne

3. SWOT analysis of Acne

4. Acne Patient Share (%) Overview at a Glance

5. Acne Market Overview at a Glance

6. Acne Disease Background and Overview

7. Acne Epidemiology and Patient Population

8. Country-Specific Patient Population of Acne

9. Acne Current Treatment and Medical Practices

10. Acne Unmet Needs

11. Acne Emerging Therapies

12. Acne Market Outlook

13. Country-Wise Acne Market Analysis (2019-2032)

14. Acne Market Access and Reimbursement of Therapies

15. Acne Market Drivers

16. Acne Market Barriers

17. Acne Appendix

18. Acne Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acne-market-on-track-for-major-expansion-by-2032-according-to-delveinsight-clinuvel-pharma-novan-dermata-therapeutics-iopharmx-bausch-health-americas-inc-kintor-pharma-solgel-technologies]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.